Clinical pharmacokinetics of topotecan

Clinical Pharmacokinetics

Volumn 31, Issue 2, 1996, Pages 85-102

  Herben, Virginie M M ^a   Ten Bokkel Huinink, Wim W ^a   Beijnen, Jos H ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; CAMPTOTHECIN DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CREATININE; DNA TOPOISOMERASE; LACTONE; METHANOL; TARTARIC ACID; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD SAMPLING; BONE MARROW TOXICITY; CHEMICAL STRUCTURE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HYDROLYSIS; DRUG STABILITY; ENZYME INHIBITION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; KIDNEY DISEASE; LIVER DISEASE; LUNG SMALL CELL CANCER; META ANALYSIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PH; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PLASMA; PRIORITY JOURNAL; REVIEW; STORAGE;

EID: 0029947777     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199631020-00001     Document Type: Review

References (71)

1. Costin D, Potmesil M. Preclinical and clinical development of camptothecins. Adv Pharmacol 1994; 29B: 51-72
2. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumour inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88: 3888-90
3. Horwitz, SB, Chang C-K, Grollman AP. Studies on camptothecin. 1. Effects on nucleic acid and protein synthesis. Mol Pharmacol 1971; 7: 632-44
4. Kessel D, Bosmann HB, Lohr K. Camptothecin effects on DNA synthesis on murine leukaemia cells. Biochim Biophys Acta 1972; 269: 210-6
5. Gottlieb JA, Guarino AM, Call JB, et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium. Cancer Chemother Rep 1970; 54: 461-70
6. Moertel CG, Schutt AJ, Reitemeier RJ, et al. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972; 56: 95-7
7. Muggia FM, Creaven PJ, Hansen H, et al. Phase I clinical trial of weekly and daily treatment with camptothecin: correlation with preclinical studies. Cancer Chemother Rep 1972; 56: 515-21
8. Hsiang Y-H, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-5
9. Hsiang Y-H, Liu LF. Identification DNA mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48: 1722-6
10. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8
11. Husain I. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994; 54: 539-46
12. McLeod HL, Douglas F, Oates M, et al. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 1994; 59: 607-11
13. Jaxel C, Kohn KW, Wani MC, et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase. I. Evidence of a specific receptor site and for a relation to antitumor activity. Cancer Res 1989; 49: 1465-9
14. Hsiang Y-H, Liu LF, Wall ME, et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 1989; 49: 4385-9
15. Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32: 715-20
16. O'Dwyer PJ, Lacreta FP, Haas NB, et al. Clinical, pharmacokinetic and biological studies of topotecan. Cancer Chemother Pharmacol 1994; 34: 46S-52S
17. Von Hoff DD, Burris HA III, Eckardt J, et al. Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 1994; 34: 41S-45S
18. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 1994; 20: 73-96
19. Verweij J, ten Bokkel Huinink W, Lund B, et al. Clinical trials of topotecan in Europe. In: Potmesil M, Pinedo H, editors. Camptothecins: new anticancer agents. Boca Raton: CRC Press, 1995: 105-12
20. Underberg WJM, Goossen RMJ, Smith BR. Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 1990; 8: 681-3
21. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992; 81: 676-84
22. Rosing H, Doyle E, Davies BE, et al. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chromotogr B Biomed Appl 1995; 668: 107-11
23. Beijnen JH, Smith BR, Keijer WJ, et al. High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal 1990; 8: 789-94
24. Burke TG, Munshi CB, Mi Z. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 1995; 84: 518-9
25. Grochow LB, Rowinsky EK, Johnson R, et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 1992; 20: 706-13
26. Saltz L, Sirott M, Young C, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993; 85: 1499-507
27. Burris III HA, Awada A, Kuhn JG, et al. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anticancer Drugs 1994; 5: 394-402
28. Van Warmerdam LJC, Creemers GJ, Rodenhuis S, et al. Pharmacokinetics and pharmacodynamics of topotecan administered at a daily times five schedule in phase II clinical trials using a limited sampling procedure. Cancer Chemother Pharmacol 1996; 38: 254-60
29. Van Warmerdam LJC, ten Bokkel Huinink WW, Rodenhuis S, et al. Phase 1 clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion [published erratum appears in J Clin Oncol 1996; 14: 689]. J Clin Oncol 1995; 13: 1768-76
30. Tong W, Saltz L, Sirott M, et al. Rapid HPLC assay for topoteam [abstract]. Proc Am Assoc Cancer Res 1991; 32: 433
31. Loos WJ, Stoter G, Verweij J, et al. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy-acid) in human plasma and urine. J Chromotogr B Biomed Appl 1996; 678: 309-15
32. Plaxe S, Christen R, O'Quigley J, et al. Phase I trial of intraperitoneal topotecan [abstract]. Proc Am Soc Clin Oncol 1993; 12: 140
33. Wall JG, Burris III HA, Von Hoff DD, et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992; 3: 337-45
34. Hasegawa K, Nishimura R, Fukuoka M, et al. Phase I and pharmacologic evaluation of topotecan on a 30 minute infusion [abstract]. Proc Am Assoc Cancer Res 1993; 34: 421
35. Verweij J, Lund B, Beijnen J, et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993; 4: 673-8
36. Haas NB, LaCreta FP, Walczak J, et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 1994; 54: 1220-6
37. Blaney SM, Balis FM, Cole DE, et al. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993; 53: 1032-6
38. Reid JM, Burch PA, Benson LM, et al. Phase I clinical and pharmacological evaluation of topotecan administered by a 24 hour continuous infusion [abstract]. Proc Am Assoc Cancer Res 1992; 33: 259
39. Abbruzzese JL, Madden T, Schmidt S, et al. Phase I trial of topotecan administered by 24-hour infusion without and with G-CSF [abstract]. Proc Am Assoc Cancer Res 1993; 34: 329
40. Stewart CF, Baker SD, Heideman RL, et al. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 1994; 12: 1946-54
41. Rowinsky EK, Adjei A, Donehower RC, et al. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994; 12: 2193-203
42. Hochster H, Liebes L, Speyer J, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994; 12: 553-9
43. Rowinsky EK, Grochow LB, Hendriks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647-56
44. Van Warmerdam LJC, Verweij J, Schellens JHM, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995; 35: 237-45
45. Herben VMM, ten Bokkel Huinink WW, Schot M, et al. Continuous infusion of low dose topotecan: a clinical pharmacologic phase II study in patients with small cell lung cancer [abstract]. Sixth Conference on DNA Topoisomerases in Therapy: 1995 Sep 6-8; Amsterdam, 77
46. Creemers GJ, Gerrits CHJ, Planting AST, et al. Phase II study with topotecan administered as a 21-day continuous infusion to patients with colorectal cancer [abstract]. Eur J Cancer 1995; 31A: S146
47. Pratt CB, Stewart C, Santana VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994; 12: 539-43
48. Topotecan (SK&F 104864-A): investigator brochure. Philadelphia: Smith, Kline and French Laboratories, 1990
49. Cole DE, Blaney SM, Balis FM. Topotecan in physiologic fluids: depot of active drug in red blood cells. Proc Am Assoc Cancer Res 1995; 36: 363
50. Munshi CB, Mi Z, Burke TG. The biophysics underlying the favorable stability of the topotecan anticancer drug in human blood [abstract]. Proc Am Assoc Cancer Res 1995; 36: 444
51. Burke T, Mi Z, Roy D, et al. The pivotal role of albumin in determining the relative blood stabilities of camptothecin analogs presently in clinical trials [abstract]. Proc Am Soc Clin Oncol 1995; 14: 463
52. Baker SD, Heideman RI, Kuttesch JF, et al. CNS penetration of topotecan following continuous infusion in children with cancer. Clin Pharmacol Ther 1994; 55: 189
53. Van Warmerdam LJC, Rosing H, ten Bokkel Huinink WW, et al. Do topotecan concentrations in saliva reflect plasma concentrations? J Oncol Pharm Pract 1995; 1: 41-5
54. Scott DO, Bindra DS, Sutton SC, et al. Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats. Drug Metab Dispos 1994; 22: 438-42
55. Recondo G, Abbruzzese J, Newman B, et al. A phase I trial of topotecan administered by a 24-hr infusion [abstract]. Proc Am Assoc Cancer Res 1991; 32: 206
56. Borkowski JM, Duerr M, Donehower RC, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 1994; 33: 493-6
57. Van Warmerdam LJC, Verweij J, Rosing H, et al. Limited sampling models for topotecan pharmacokinetics. Ann Oncol 1994; 5: 259-64
58. Leonard TB, Fish CJ, Smith B, et al. Toxicity and toxicokinetics of topotecan in dogs following intravenous and oral administration [abstract]. Proc Am Assoc Cancer Res 1994; 35: 461
59. Davies BE, Minthorn EA, Dennis M, et al. The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog [abstract]. Eur J Cancer 1995; 31A: S192
60. Creemers GJ, Schellens JHM, Beijnen JH, et al. Bioavailability of oral topotecan, a new topoisomerase I inhibitor [abstract]. Proc Am Soc Clin Oncol 1994; 13: 132
61. Eckardt J, Burris H, Rizzo J, et al. A phase I safety and bioavailability study of oral topotecan [abstract]. Eur J Cancer 1995; 31A: S193
62. Schellens JHM, Eckardt JR, Verweij J, et al. Pharmacokinetics, clinical pharmacodynamics and safety of chronic oral topotecan in a phase I study [abstract]. Eur J Cancer 1995; 31A: S28
63. Cheng H, Jusko WJ. Pharmacokinetics of reversible metabolic systems. Biopharm Drug Dispos 1993; 14: 721-66
64. Grochow LB, Slichenmyer W, Rowinsky E, et al. Phase I clinical and pharmacologic study of topotecan in patients with hepatic or renal dysfunction [abstract]. Eighth NCI-EORTC Symposium on New Drugs in Cancer Chemotherapy; 1994 Mar 15-18; Amsterdam, 19
65. Slichenmyer W, Chen T-L, Donehower R, et al. Clinical pharmacology of topotecan in cancer patients with renal or hepatic dysfunction [abstract]. Proc Am Soc Clin Oncol 1994; 13: 142
66. Zamboni WC, Heideman RL, Meyer WH, et al. Pharmacokinetics (PK) of topotecan (TPT) in pediatric patients with normal and altered renal function [abstract]. Proc Am Soc Clin Oncol 1996; 15: 180
67. Burris III HA, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units. J Natl Cancer Inst 1992; 84: 1816-20
68. Houghton PJ, Cheshire PJ, Hallman II JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36: 393-403
69. Hochster H, Liebes L, Sorich J, et al. Increasing cleavable complex formation in peripheral blood lymphocytes with increasing topotecan infusion duration: a rationale for prolonged administration of camptothecins [abstract]. Sixth Conference on DNA Topoisomerases in Therapy. 1995 Sep 6-8; Amsterdam, 88
70. Hutson PR, Kim K, Johnson D, et al. Pharmacodynamic evaluation of the response of extensive stage small cell lung cancer to topotecan [abstract]. Proc Am Soc Clin Oncol 1995; 14: 460
71. Stewart CF, Baker SD, Furman WL, et al. Targeting plasma concentrations of topotecan during a 120-hr continuous infusion in children with relapsed acute leukemia [abstract]. Clin Pharmacol Ther 1995; 57: 176